FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038393150> ?p ?o ?g. }

• W2038393150 endingPage "1940" @default.
• W2038393150 startingPage "1935" @default.
• W2038393150 abstract "Tadalafil, a phosphodiesterase type 5 inhibitor, is effective therapy for erectile dysfunction (ED). Men with ED have a high incidence of comorbid conditions including cardiovascular disease, diabetes mellitus and benign prostatic hyperplasia. Although phosphodiesterase type 5 inhibitors are safe when administered with most medications, sildenafil given with doxazosin and vardenafil given with terazosin evoke orthostatic hypotension in some patients. We examined the hemodynamic interactions of tadalafil with the alpha-blockers doxazosin and tamsulosin.In separate double-blind, placebo controlled, randomized crossover studies (18 patients in each study) we evaluated the hemodynamic effects of doxazosin 8 mg with tadalafil 20 mg, and tamsulosin 0.4 mg with tadalafil 10 and 20 mg. Blood pressure (BP) and heart rate were recorded before dosing and for 24 hours after dosing.Tadalafil 20 mg augmented the hypotensive effect of doxazosin by producing a mean maximal decrease in standing systolic BP (SBP) that was significantly greater than placebo (a mean difference of 9.8 mm Hg). Analysis of BP outliers showed that the number of subjects with a standing SBP of less than 85 mm Hg was greater after doxazosin plus tadalafil (28%) versus doxazosin plus placebo (6%). In subjects on tamsulosin, tadalafil 10 and 20 mg produced mean maximal decreases in standing SBP that were similar to placebo (mean difference of 1.7 and 2.3 mm Hg, respectively). No subject taking tamsulosin had a decrease in standing SBP less than 85 mm Hg.Tadalafil augmented the hypotensive effects of doxazosin but had little hemodynamic interaction with tamsulosin. In patients taking tadalafil for ED, tamsulosin 0.4 mg may be given for the treatment of benign prostatic hyperplasia." @default.
• W2038393150 created "2016-06-24" @default.
• W2038393150 creator A5015839705 @default.
• W2038393150 creator A5024625820 @default.
• W2038393150 creator A5028319151 @default.
• W2038393150 creator A5045607351 @default.
• W2038393150 creator A5057024394 @default.
• W2038393150 creator A5060925457 @default.
• W2038393150 creator A5082683482 @default.
• W2038393150 date "2004-11-01" @default.
• W2038393150 modified "2023-10-18" @default.
• W2038393150 title "INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MEN" @default.
• W2038393150 cites W1504325369 @default.
• W2038393150 cites W1967694704 @default.
• W2038393150 cites W1967851670 @default.
• W2038393150 cites W1971406218 @default.
• W2038393150 cites W1983322061 @default.
• W2038393150 cites W2008949374 @default.
• W2038393150 cites W2038961111 @default.
• W2038393150 cites W2062957055 @default.
• W2038393150 cites W2064690405 @default.
• W2038393150 cites W2073482879 @default.
• W2038393150 cites W2096596833 @default.
• W2038393150 cites W2121939064 @default.
• W2038393150 cites W2132288985 @default.
• W2038393150 cites W2154951602 @default.
• W2038393150 cites W22857079 @default.
• W2038393150 cites W2297358297 @default.
• W2038393150 doi "https://doi.org/10.1097/01.ju.0000142687.75577.e4" @default.
• W2038393150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15540759" @default.
• W2038393150 hasPublicationYear "2004" @default.
• W2038393150 type Work @default.
• W2038393150 sameAs 2038393150 @default.
• W2038393150 citedByCount "139" @default.
• W2038393150 countsByYear W20383931502012 @default.
• W2038393150 countsByYear W20383931502013 @default.
• W2038393150 countsByYear W20383931502014 @default.
• W2038393150 countsByYear W20383931502015 @default.
• W2038393150 countsByYear W20383931502016 @default.
• W2038393150 countsByYear W20383931502017 @default.
• W2038393150 countsByYear W20383931502018 @default.
• W2038393150 countsByYear W20383931502019 @default.
• W2038393150 countsByYear W20383931502020 @default.
• W2038393150 countsByYear W20383931502021 @default.
• W2038393150 countsByYear W20383931502022 @default.
• W2038393150 countsByYear W20383931502023 @default.
• W2038393150 crossrefType "journal-article" @default.
• W2038393150 hasAuthorship W2038393150A5015839705 @default.
• W2038393150 hasAuthorship W2038393150A5024625820 @default.
• W2038393150 hasAuthorship W2038393150A5028319151 @default.
• W2038393150 hasAuthorship W2038393150A5045607351 @default.
• W2038393150 hasAuthorship W2038393150A5057024394 @default.
• W2038393150 hasAuthorship W2038393150A5060925457 @default.
• W2038393150 hasAuthorship W2038393150A5082683482 @default.
• W2038393150 hasConcept C126322002 @default.
• W2038393150 hasConcept C126894567 @default.
• W2038393150 hasConcept C142724271 @default.
• W2038393150 hasConcept C178853913 @default.
• W2038393150 hasConcept C204787440 @default.
• W2038393150 hasConcept C27081682 @default.
• W2038393150 hasConcept C2776679619 @default.
• W2038393150 hasConcept C2777562237 @default.
• W2038393150 hasConcept C2777590997 @default.
• W2038393150 hasConcept C2779929075 @default.
• W2038393150 hasConcept C2780542891 @default.
• W2038393150 hasConcept C2780816001 @default.
• W2038393150 hasConcept C42219234 @default.
• W2038393150 hasConcept C71924100 @default.
• W2038393150 hasConcept C73787029 @default.
• W2038393150 hasConcept C74534348 @default.
• W2038393150 hasConcept C84393581 @default.
• W2038393150 hasConcept C98274493 @default.
• W2038393150 hasConceptScore W2038393150C126322002 @default.
• W2038393150 hasConceptScore W2038393150C126894567 @default.
• W2038393150 hasConceptScore W2038393150C142724271 @default.
• W2038393150 hasConceptScore W2038393150C178853913 @default.
• W2038393150 hasConceptScore W2038393150C204787440 @default.
• W2038393150 hasConceptScore W2038393150C27081682 @default.
• W2038393150 hasConceptScore W2038393150C2776679619 @default.
• W2038393150 hasConceptScore W2038393150C2777562237 @default.
• W2038393150 hasConceptScore W2038393150C2777590997 @default.
• W2038393150 hasConceptScore W2038393150C2779929075 @default.
• W2038393150 hasConceptScore W2038393150C2780542891 @default.
• W2038393150 hasConceptScore W2038393150C2780816001 @default.
• W2038393150 hasConceptScore W2038393150C42219234 @default.
• W2038393150 hasConceptScore W2038393150C71924100 @default.
• W2038393150 hasConceptScore W2038393150C73787029 @default.
• W2038393150 hasConceptScore W2038393150C74534348 @default.
• W2038393150 hasConceptScore W2038393150C84393581 @default.
• W2038393150 hasConceptScore W2038393150C98274493 @default.
• W2038393150 hasIssue "5" @default.
• W2038393150 hasLocation W20383931501 @default.
• W2038393150 hasLocation W20383931502 @default.
• W2038393150 hasOpenAccess W2038393150 @default.
• W2038393150 hasPrimaryLocation W20383931501 @default.
• W2038393150 hasRelatedWork W1958430778 @default.
• W2038393150 hasRelatedWork W1982254958 @default.
• W2038393150 hasRelatedWork W2038393150 @default.

• next